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Abstract
The treatment of multi-drug resistant (MDR) cancer is a clinical challenge. Many MDR cells over-express epidermal growth
factor receptor (EGFR). We exploit this expression through the development of EGFR-targeted, polymer blend nanocarriers
for the treatment of MDR cancer using paclitaxel (a common chemotherapeutic agent) and lonidamine (an experimental
drug; mitochondrial hexokinase 2 inhibitor). An orthotopic model of MDR human breast cancer was developed in nude mice
and used to evaluate the safety and efficacy of nanoparticle treatment. The efficacy parameters included tumor volume
measurements from day 0 through 28 days post-treatment, terminal tumor weight measurements, tumor density and
morphology assessment through hematoxylin and eosin staining of excised tumors, and immunohistochemistry of tumor
sections for MDR protein markers (P-glycoprotein, Hypoxia Inducible Factor, EGFR, Hexokinase 2, and Stem Cell Factor).
Toxicity was assessed by tracking changes in animal body weight from day 0 through 28 days post-treatment, by measuring
plasma levels of the liver enzymes ALT (Alanine Aminotransferase) and LDH (lactate dehydrogenase), and by white blood
cell and platelet counts. In these studies, this nanocarrier system demonstrated superior efficacy relative to combination
(paclitaxel/lonidamine) drug solution and single agent treatments in nanoparticle and solution form. The combination
nanoparticles were the only treatment group that decreased tumor volume, sustaining this decrease until the 28 day time
point. In addition, treatment with the EGFR-targeted lonidamine/paclitaxel nanoparticles decreased tumor density and
altered the MDR phenotype of the tumor xenografts. These EGFR-targeted combination nanoparticles were considerably
less toxic than solution treatments. Due to the flexible design and simple conjugation chemistry, this nanocarrier system
could be used as a platform for the development of other MDR cancer therapies; the use of this system for EGFR-targeted,
combination paclitaxel/lonidamine therapy is an advance in personalized medicine.
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Introduction
The development of multi-drug resistant (MDR) cancer
often impedes the clinical treatment of cancer as it results in non-
responsive disease that can lead to metastasis [1,2]. MDR refers to
a state of resilience against structurally and/or functionally
unrelated drugs [1]. MDR is often acquired through exposure to
chemotherapeutic agents but MDR can also be intrinsic (innate)
[1].
Hypoxia is an established microenvironmental selection pres-
sure that can result in MDR and resistance to radiation therapy
[3,4]. Under conditions of hypoxia and cell stress Hypoxia
Inducible Factor alpha (HIF-1a) translocates from the cytoplasm
to the nucleus; HIF-a then complexes with HIF-b, forming an
active transcription factor [3,4]. This active HIF complex is then
able to induce transcription by binding to Hypoxia Responsive
Elements (HRE’s) on target genes; target genes include P-
glycoprotein (P-gp), Epidermal Growth Factor Receptor (EGFR),
and many glycolytic proteins such as Hexokinase 2 (HXK2) [3,4].
Oxygen-independent factors such as cyclooxygenase-2 activity,
epidermal growth factor receptor (EGFR), heat-shock protein 90,
and phosphatidylinositol 3-kinase can also stabilize HIF [4,5,6].
P-gp is a transmembrane drug efflux pump of the ATP-Binding
Cassette (ABC) transporter family; P-gp expression in cancer is
associated with MDR and poor prognosis [2]. EGFR expression in
some types of cancer is also associated with aggressive disease [7].
Over expression of EGFR leads to receptor clustering in the cell
membrane which makes a cell hyper-sensitive to EGFR substrates;
this aids the survival of MDR cells, especially hypoxic tumor
regions that may be distal from a continuous nutrient supply [7].
Another survival advantage for cancer cells is to acquire energy
through glycolysis; either anaerobic (the Pasteur Effect) or aerobic
(the Warburg Effect) [8]. Many glycolytic proteins such as
hexokinase 2 are HIF targets [3,4,9]. Hexokinase catalyzes the
first step of glycolysis; the hexokinase 2 isoform is directly
associated with mitochondria and is overexpressed in many types
of cancer [4,10,11]. Mitochondrial association of hexokinase 2
prevents binding of pro-apoptotic BcL-2 family member proteins
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transition pore complex; this also aids cell survival as it prevents
cytochrome c release and the subsequent apoptotic cascade [10].
The current drug delivery system actively targets MDR cancer
cells through EGFR binding; the surface of the nanocarriers have
been modified with an EGFR-specific peptide. This system treats
MDR cancer by using a combination of paclitaxel and
lonidamine. Paclitaxel (PTX) is a common chemotherapeutic
agent that hyper-stabilizes microtubules, preventing cell division;
PTX is a non-specific agent and is associated with high residual
toxicity. Lonidamine (LON) (1-[(2,4-Dichlorophenyl)methyl]-1H-
indazole-3-carboxylic acid) is a hexokinase 2 inhibitor that has
been shown to induce apoptosis and treat MDR in various cancer
cell lines [12,13,14]. In the United States, Phase II clinical trials of
LON as a treatment for benign prostatic hyperplasia were
suspended due to associated liver toxicity [15,16]. This drug
delivery system aims to improve the efficacy and reduce the
toxicity of PTX and LON through the use of combination therapy
and active targeting.
This study examines the therapeutic efficacy and safety of
EGFR-targeted nanoparticles (NPs) loaded with PTX and LON.
These polymer-blend nanocarriers were evaluated in an ortho-
topic model of MDR breast cancer. Tumor size and growth
progression was used to assess the efficacy of therapy. The safety/
toxicity of this therapy was assessed by measuring the change in
body weight, plasma levels of the liver enzymes ALT (Alanine
Aminotransferase) and LDH (lactate dehydrogenase), and white
blood cell and platelet counts. To further characterize the efficacy
of this therapy, H & E staining of tumor sections from each group
were compared. Also, Immunohistochemistry (IHC) of the tumor
sections for expression of P-gp, HIF-1a, EGFR, HXK2, CD-31,
and Stem Cell Factor (SCF) was used to assess the MDR character
of the tumors after treatment. As demonstrated by the schema in
Figure 1, treatment with the EGFR-targeted NPs loaded with
PTX and LON decreased tumor volume and decreased the
expression of hypoxic and MDR associated proteins in the
orthotopic breast cancer model.
Results
Nanoparticle Characterization
The design objective of this nanocarrier system was to actively
target MDR cells by binding to the EGFR receptor and
subsequently deliver PTX and LON to the site of a tumor. To
achieve appreciable loading efficiency for both drugs (approxi-
mately $70%) PCL (Polycaprolactone) was used as the primary
nanoparticle constituent (formulation optimization is described in
our previously published work [17]). To achieve active targeting a
PLGA-PEG-Peptide construct was synthesized and incorporated
in the PCL (Polycaprolactone) NPs. Both a PLGA-PEG and a
PLGA-PEG-Peptide construct were incorporated in the formula-
tion to achieve surface modification with PEG and the peptide.
Figure 1. Treatment schema. Nude mice with orthotopic, multidrug resistant breast tumor xenografts were treated with EGFR-targeted, polymer
blend nanoparticles loaded with paclitaxel and lonidamine. This nanoparticle formulation is internalized via the EGFR receptor; treatment leads toa
cascade of cellular changes and a decrease in tumor volume. As assessed by immunohistochemistry of tumor xenografts, nanoparticle treatment
decreased the expression of hypoxic and MDR markers (EGFR, epidermal growth factor receptor; HIF, hypoxia inducible factor; HXK2, hexokinase 2;
Pgp, P-glycoprotein; SCF, stem cell factor).
doi:10.1371/journal.pone.0024075.g001
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particles, aiding in lonidamine and paclitaxel encapsulation while
the PEG and EGFR-specific peptide protrude from the particle
surface enabling active targeting and protection from the
reticuloendothelial system. The complete synthesis and character-
ization of this system is described in our other work [17]; NMR
was used to assess the grafting process, ESCA was used to confirm
the presence of the peptide on the surface of the NPs, drug
encapsulation and release kinetics were quantified over time, and
EGFR targeting was quantified in a panel of nine cell lines with
various levels of EGFR expression. As depicted in Figure 2, SEM
of the NPs confirmed the nanometer scale of the particles which
averaged between 120 –160 nm.
Efficacy Analysis
MDA-MB-231 tumors established from hypoxic pre-condi-
tioned cells were grown to 100 mm
3 size and then mice were
treated with one of the following 8 treatments; (1) targeted NPs
loaded with PTX and LON, (2) SOL of PTX and LON, (3)
targeted NPs loaded with PTX, (4) PTX SOL, (5) targeted NPs
loaded with LON, (6) LON SOL, (7) blank targeted NPs (no drug),
and (8) saline. Treatment proceeded for 28 days. During this time,
tumor size and body weight were monitored and blood was
collected to assess toxicity.
Figure 3.A depicts the tumor growth in each treatment group
from day 0 (date of treatment initiation) until day 28. The tumor
growth for the saline and vehicle (blank NP) treated groups is
similar; while treatment with LON SOL and LON NPs resulted in
slightly decreased tumor volume. Treatment with PTX SOL and
PTX NPs resulted in a further decrease in tumor volume.
Treatment with combination (LON and PTX) SOL actually
repressed tumor growth for 10 days, at which point growth
resumed at a much slower rate. This is illustrated in Figure 3.B
along with the combination NP treatment. The combination NPs
were the only treatment group that actually decreased tumor
volume, sustaining this decrease until the 28 day time point when
the tumor volume approached the initial tumor volume.
A Two-way ANOVA test was used to analyze the data; the
results are presented in Table 1. There was no significance for
any time point between the saline and vehicle treated groups. For
this reason, comparisons of each group with the vehicle treatment
group were not included in Table 1. Table 1 compares the
treatment groups and lists the day post-treatment that a specific
level of significance was reached. Most notably, between 4 and 12
days, there is significance between both the combination SOL
group and the combination NP group compared to saline, LON
SOL, LON NPs, PTX SOL, and PTX NP treatments. There is
also significance between the combination SOL group and the
combination NP group after 10 days of treatment.
The tumor weights from each group are presented in
Figure 3.C. The mean tumor volume on day 28 (sacrifice) is
indicated above the bar for each group. The tumor weights
correspond with the terminal tumor volume data. Combination
therapy with EGFR-targeted NPs was significantly more effective
at reducing tumor volume than single agent treatment.
Safety and Toxicity Profiles
The body weight of each group was also monitored throughout
the course of treatment and is presented in Figure 3.D. All SOL
groups underwent an initial decrease in body weight, which
remained lower throughout the course of treatment. This effect
was the most pronounced for the combination SOL. The groups
treated with PTX NPs and with the combination NPs also
underwent an initial decline in body weight; however, there was a
moderate recovery of this decline between 7-10 days post-
treatment. The initial and sustained decline of the SOL groups
is most likely due to the CremophorH EL solution. The decline in
body weight associated with the combination NPs and the PTX
NPs is most likely due to the cytotoxicity of PTX.
Blood samples were also collected on day 0, day 14, and day 28
of treatment and were analyzed for levels of LDH and ALT as well
as white blood cell and platelet counts. The results of the day 14
blood analysis are portrayed in Figure 4; for all four parameters,
there was no significance between any treatment group at day 0.
LDH (Figure 4.A) is often elevated in cancer and due to tissue
damage, as such; it is a common marker for disease and toxicity.
At day 14 there was significance between the saline group and the
group treated with PTX SOL as well as the group treated with
combination SOL. There was significance between the No Tumor
group and all treatment groups at day 14 (p,0.01) and at day 28
(p,0.05; Figure S1). This is most likely due to the growth of the
tumor itself, and not directly associated with the treatment
administered to each group. An increase in ALT (Figure 4.B)i s
often associated with liver damage. At day 14, there was
significance between the saline group and all SOL groups. Of
importance, at this time point there was also significance between
the combination SOL and the combination NPs. Combination
LON/PTX therapy with NPs results in less liver toxicity than
treatment with combination SOL. There was also significance
between the No Tumor group (and the Vehicle group) and all
SOL treatment groups at day 14 (p,0.01 for No Tumor
comparison, p,0.05 for Vehicle comparison).
A decrease in platelet counts (Figure 4.C) is often associated
with chemotherapy toxicity. At day 14, there was significance
between the No Tumor group and all SOL groups. At this time
point there was also significance between the saline (and vehicle)
group and all SOL groups. Elevated WBC counts (Figure 4.D)
are indicative of tissue damage. Consistent with the other toxicity
data, there is significance between the saline and vehicle treated
groups and all of the SOL treated groups. There is also
significance between each SOL group and the corresponding
NP group. The NP treatments are less toxic than SOL drug
treatments. There is significance between the No Tumor group
and all other groups. As this difference is apparent in the saline
and vehicle groups also, it is most likely an indication of tissue
Figure 2. SEM of nanoparticles. The nanometer size of the
nanocarriers was confirmed with a scanning electron micrograph of
the nanoparticles. The scale bar is 2 mm.
doi:10.1371/journal.pone.0024075.g002
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Collectively, the blood analysis indicates that NP therapy is
significantly less toxic than SOL drug treatment.
Histology
To further assess toxicity, hematoxylin and eosin staining of
tumor sections from each treatment group were examined
(Figure 5). Images of both the tumor perimeter and the tumor
core were acquired. Common to all tumor sections, is the
haphazard array of cell growth. Each tumor has a clear
demarcation of increased cell density in the perimeter of the tumor.
This perimeter, however, is not consistent between the treatment
groups. The saline treated group, the group treated with blank NPs,
and the group treated with LON SOL appear to have a much
thicker tumor boundary of cells. This appears slightly decreased in
the LON NP treated group, and more markedly decreased in the
groups treated with PTX SOL, PTX NPs, combination SOL, and
combination NPs. The core density appears to follow a similar
pattern as the perimeter density in the treatment groups. The cell
density in the tumor core sections of the saline group, the blank NP
group, the LON SOL group, and the LON NP group seem much
higher than the cell densities of the PTX SOL group, the PTX NP
group, the combination SOL group, and the combination NP
group.ThedecreasedcelldensityofthecombinationNPgroup may
explain the dramatic decrease in the final tumor weight. These
decreases in density may be a hallmark of effective treatment.
IHC of tumor section from each group were analyzed for
expression the following six proteins; P-gp, HIF-1a, EGFR, CD-
31, HXK2, and SCF (Figure 6–8). For each section, F-actin is
stained with phalloidin (red), nuclei are stained with Hoechst
33342 (blue), and the protein of interest is labeled with secondary
antibodies that are Alexa FluorH 488 conjugated (green).
P-gp expression (Figure 6) was very high in the saline group,
the blank NP group, and in the LON SOL group. There appeared
Figure 3. Tumor volume, tumor weight, and body weight after treatment. Efficacy of the combination nanoparticle therapy was assessed by
measuring changes in tumor volume from 0–28 days post-treatment and by measuring the terminal tumor weight at 28 days post-treatment. Day 0
was the first day of treatment. Body weight was used as a toxicity parameter and was measured from 0–28 days post-treatment. For all graphs, each
data point represents the mean 6 SD with an n=4.(A) Tumor volume. Mice were treated with one of eight treatments via tail vein injection; saline
(black circles), vehicle (blank nanoparticles; gray squares), lonidamine solution (LON Sol; green triangles), lonidamine nanoparticles (LON NP; purple
inverted triangles); paclitaxel solution (PTX Sol; light blue diamonds), paclitaxel nanoparticles (PTX NP; orange open circles), lonidamine and paclitaxel
combination solution (LON + PTX Sol; dark blue asterisks), and lonidamine and paclitaxel combination nanoparticles (LON + PTX NP; light green stars).
(B) Tumor volume (of combination therapy). To clarify the difference between lonidamine and paclitaxel combination treatment in solution form
(LON + PTX Sol; open circles) compared to nanoparticle treatment (LON + PTX NP; closed circles), these two groups were graphed separately here. (C)
Tumor weight. The terminal tumor weight (at 28-days post-treatment) was plotted for each treatment group. The number above each bar represents
the average terminal tumor volume (from panel A). The asterisks directly above the error bars indicate significance between saline and the indicated
group (*p,0.05, ***p,0.001). (D) Body weight. Body weight was measured and plotted as percent change (relative to initial body weight) from 0–28
days post-treatment. The groups include; no tumor (black circles), saline (gray squares), vehicle (green triangles), lonidamine solution (LON Sol; purple
inverted triangles), lonidamine nanoparticles (LON NP; light blue diamonds), paclitaxel solution (PTX Sol; orange open circles); paclitaxel nanoparticles
(dark blue open squares), lonidamine and paclitaxel combination solution (LON + PTX Sol; light green open triangles), and lonidamine and paclitaxel
combination nanoparticles (LON + PTX NP; pink inverted open triangles).
doi:10.1371/journal.pone.0024075.g003
Efficacy of EGFR-Targeted PTX/LON Nanoparticles
PLoS ONE | www.plosone.org 4 September 2011 | Volume 6 | Issue 9 | e24075to be a slight decrease in the LON NP group, the PTX SOL
group, the PTX NP group and the combination SOL group.
There was a more remarkable decrease in the combination NP
group. It is possible that a month of treatment with combination
therapy begins to reverse MDR when administered as SOL (slight
decrease in P-gp), but more completely reverses MDR when
administered as NP treatment (dramatic decrease).
HIF-1a (Figure 6) was very high in the saline group, blank NP
treated group, PTX SOL group, and PTX NP group. In these
sections with high expression, HIF-1a appears to be co-localized
with both the cytoplasmic cell fraction (yellow and green) and with
the nucleus of cells (white). LON SOL treatment and more
remarkably, LON NP treatment decreased HIF-1a expression. As
LON inhibits hexokinase 2 (and the Warburg effect), this decrease
in HIF-1a expression may be due to the feedback loop between
the glycolitic and HIF pathways. There is a further decrease in
HIF-1a expression with the combination treatment. LON may
decrease the Warburg effect, decrease the activity of the HIF
pathway, and sensitize the tumor to the effects of PTX, leading to
MDR reversal.
There was a very high level of EGFR (Figure 7) expression in
all of the tissue sections; however the combination NP group
appeared to have slightly lower levels relative to the other groups.
This may indicate that the aggressiveness and overall character of
the tumor has transformed. On the other hand, CD-31 (Figure 7)
expression was low/non-detectable in all tumor sections. CD-31
was included as a marker for angiogenesis.
The expression of HXK2 (Figure 8) followed a similar pattern
to HIF-1a expression. There was a high level of expression in the
saline treated group, the blank NP group, the PTX SOL group,
and the PTX NP group. There was a decrease in HXK2 expre-
ssion in the LON SOL treated group and a further decrease in the
LON NP treated group, the combination SOL group, and the
combination NP group. LON NPs appear to have more of an
effect on HXK2 expression than LON SOL, and this effect seems
to be enhanced with combination therapy.
The last protein that was examined was SCF (Figure 8). There
was a moderate level of SCF expression in the saline treated group;
this expression appeared more co-localized with F-actin (yellow) in
the blank NP treated group; and appeared more co-localized with
cell nuclei (white) in the LON SOL group, the PTX SOL group,
and the PTX NP group. There appeared to be both F-actin and
nucleic co-localization in the combination SOL treated group while
there was a marked decrease in expression in the LON NP group
and a further decrease in the combination NP treated group.
Collectively, the saline and blank NP treated groups have higher
expression levels of P-gp, HIF-1a, EGFR, and HXK2 relative to
the other treatment groups. Treatment with combination NPs
resulted in a decrease in expression of P-gp, HIF-1a, EGFR,
HXK2 and SCF relative to the other groups. Although less
remarkable, treatment with the combination SOL demonstrated a
similar pattern. This indicates that combination treatment does
indeed transform the innate character of the MDR tumors.
Discussion
The complete in vitro characterization of this drug delivery
system demonstrated the improved efficacy of combination PTX/
LON therapy, EGFR binding of the NPs, and sustained drug
release of the system [17]. We developed a novel, orthotopic
model of MDR human breast cancer using hypoxic pre-
conditioned cells to establish tumor xenografts in nude mice
(submitted for publication and briefly described in this work).
Using this in vivo model, evaluations of this EGFR-targeted NP
system demonstrated that these particles had a superior pharma-
cokinetic profile (TK,AUC0-‘,AUMC0-‘, and MRT0-‘) relative to
a comparable non-targeted NP system [18]. The current research
demonstrates that treatment with EGFR-targeted LON/PTX NPs
is more effective than combination SOL treatment (decreased
tumor volume and decreased tumor weight). The increased
efficacy of NP treatment may be due to the enhanced permeability
and retention effect and active targeting. Although combination
therapy with drug SOL was also effective relative to single agent
treatment, the toxicity associated with SOL treatment was much
higher compared to NP treatment. The combination NPs resulted
in less of a decrease in body weight and more of a recovery in body
weight, less LDH, less ALT, lower WBC counts, and higher
platelet counts. The higher toxicity of SOL treatment relative to
the NPs is most likely due to the effects of CremophorH EL. The
significance between the saline group and the PTX SOL group as
well as the combination SOL group is most likely due to a
synergist combination of the cytotoxicty of PTX and the toxicity of
the CremophorH EL SOL. NP treatment is a safer alternative to
combination drug SOL. Qualitative analysis demonstrated that
combination NP treatment resulted in a more dramatic decrease
in tumor core and perimeter density relative to combination SOL.
This change in density may be proportional to the therapeutic
effect.
Table 1. Two-Way ANOVA of tumor growth.
Comparison
Significance Level,
Days Post-Treatment
Treatment A Treatment B
p
,0.05
p
,0.01
p
,0.001
Saline LON SOL --- 14 18
Saline LON NP --- 10 12
Saline PTX SOL --- --- 6
Saline PTX NP 4 --- 6
Saline LON + PTX SOL --- --- 4
Saline LON + PTX NP --- --- 4
LON SOL LON NP 22 --- ---
LON SOL PTX SOL 8 --- 10
LON SOL PTX NP 6 7 8
LON SOL LON + PTX SOL 4 --- 6
LON SOL LON + PTX NP --- --- 4
LON NP PTX SOL 14 16 20
LON NP PTX NP 8 10 14
LON NP LON + PTX SOL --- --- 6
LON NP LON + PTX NP --- 4 6
PTX SOL PTX NP 18 21 ---
PTX SOL LON + PTX SOL 7 8 12
PTX SOL LON + PTX NP --- --- 6
PTX NP LON + PTX SOL 12 14 18
PTX NP LON + PTX NP --- 6 7
LON + PTX SOL LON + PTX NP 10 20 ---
GraphPad PrismH Software was used to perform a two-way ANOVA of the
tumor growth data after treatment (this data is graphed as Tumor Volume from
0-28 days post-treatment in Figure 3.A). Treatment A (first column) was
compared to treatment B (second column) and the time is took (in days-post-
treatment) to reach a significance level of p,0.05, p,0.01, and p,0.001 are
listed in columns three, four, and five respectively.
doi:10.1371/journal.pone.0024075.t001
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strated a more pronounced decrease in the expression of Pgp,
HIF-1a, EGFR, HXK2, and SCF after treatment with combina-
tion NPs. SCF was included in the IHC analysis to examine if
treatment had an effect on the expression of SCF and to examine
if SCF is indeed a marker for MDR in this tumor model. It
appears that two core concepts of cancer stem cells co-exist; there
are cancer initiating stem cells that originate as stem cells, but
transform into cancer causing cells and secondly, there are cancer
derived stem cells which are cancer cells that develop stem-like
properties, these cells are better known as MDR cells. In line with
the concept that MDR cells can develop stem-like properties and
be identified as cancer stem cells, different studies have shown that
cell stressors such as hypoxia, which are efficient in inducing
cancer aggression and MDR phenotypes, also induce stem-like
properties in cancer cells such as the expression of stem cell factor
(SCF) [3,4,9,19,20]. It may be that as the tumors become less
hypoxic (LON NPs and combination NPs), SCF also decreases.
The differential co-localization of SCF may be attributed to its role
in many different signally pathways such as the c-kit pathway; also
there is a soluble and transmembrane form of SCF. The different
treatments may alter distinct signally pathways dominated by one
of the SCF isoforms.
Overall, the IHC demonstrated that combination NP treatment
appears to change the phenotype of the tumor, decreasing the
MDR character of the xenografts (Figure 1). Collectively, the
EGFR-targeted NPs were more effective in treating MDR than
SOL and single agent treatments and less toxic than the SOL
treatments. This nanocarrier system is a stepping stone on the road
to personalized medicine.
Concluding Remarks
Treating MDR with a cocktail of chemotherapeutic agents is a
common clinical approach. However, as MDR is a dynamic
disease state, many of the current drug combinations are rendered
ineffective after perpetual use. As such, there is a demand for new
drug combinations for treating MDR. There is also a clinical need
to reduce the toxicity associated with these treatments as toxicity
Figure 4. Toxicity analysis. Liver enzymes and blood counts were used to assess toxicity. For all graphs, each data point represents the mean 6
SD with an n=4. The double dagger represents significance between the No Tumor group and all other groups ({ p,0.05, {{ p,0.01, {{{ p,0.0001).
The section sign represents significance between the indicated group and all solution groups (1 p,0.05, 11 p,0.01, 111 p,0.0001). The asterisks
directly above the bars (no brackets) represents significance between that group and the saline group whereas asterisks above brackets indicate
inter-group significance (*p,0.05, **p,0.01, ***p,0.0001). (A) Lactate dehydrogenase (LDH). (B) Alanine Aminotransferase (ALT). (C) Platelet Counts.
(D) White Blood Cell (WBC) Counts.
doi:10.1371/journal.pone.0024075.g004
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PLoS ONE | www.plosone.org 6 September 2011 | Volume 6 | Issue 9 | e24075Figure 5. Histology of tumor perimeters and cores. Tissue sections were stained with hematoxylin and eosin. The nuclei are stained with
hematoxylin (blueish color) while other cell fractions are stained with eosin (red and pink colors).
doi:10.1371/journal.pone.0024075.g005
Figure 6. Immunohistochemistry of P-gp and HIF-1a. Tissue sections were probed with primary antibodies against the protein of interest, then
labeled with Alexa FluorH 488 conjugated secondary antibodies (green). F-actin was stained with Alexa FluorH 568 phalloidin (red) and nuclei were
stained with Hoechst 33342 (blue).
doi:10.1371/journal.pone.0024075.g006
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interval which can aid the development of acquired MDR.
Combination LON/PTX therapy using EGFR-targeted NPs
represents a new approach for the treatment of MDR cancer;
this approach addresses the clinical demand for new drug
combinations and provides a solution to chemotherapy associated
toxicity through the use of a nanocarrier system.
Materials and Methods
Polymer and Peptide Conjugation
This nanocarrier system has been completely characterized and
described in our other works [17,18]. The peptide GE11 was used
to accomplish active targeting of the EGF receptor; this is an
established EGFR ligand with the following sequence: YHWY-
GYTPQNVIGGGGC [21,22]. Conjugation of GE11 to the
PLGA-PEG construct was achieved using maleimide/cysteine
linakge (the PEG residue has a terminal maleimide while the
peptide has a terminal cysteine). GE11 was synthesized by Tufts
University Core Facility, Boston, MA. To synthesize both the
PLGA-PEG-peptide and PLGA-PEG constructs, 50:50 poly(DL-
lactide-co-glycolide) (PLGA) with an inherent viscosity of 0.15-0.25
(Durect LactelH Adsorbable Polymers; Pelham, AL) was used;
amine- poly(ethylene glycol) PEG-maleimide (MW 2000; JenKem
Technology; Allen, TX) was used for the PLGA-PEG-peptide
construct, while m-PEG-amine (MW 2000; LaysanBio; Arab, AL)
was used to synthesize the PLGA-PEG construct. For complete
details of the construct synthesis, please refer to our prior
publication [17].
Nanoparticle and Drug Solution Preparations
An established solvent displacement method was used to
synthesize the NPs [23]. Poly(e-caprolactone) (PCL; average
MW 14.8 kDa; Polysciences, Inc., Warrington, PA) was used as
the primary NP constituent. PCL, the PLGA-PEG-peptide
construct, and the therapeutic agents were dissolved in 2 mL
50/50 acetonitrile/DMF then incubated in a 37uC water bath for
10 minutes. This SOL was then added dropwise to 20 mL
distilled, deionized water while stirring, covered with aerated
parafilm, allowed to stir overnight, centrifuged at 10,000 g for 30
minutes, and then resuspened in di water. The PLGA-PEG-
peptide conjugate was added to the NP formulation at 20% w/w
total polymer. An additional 10% w/w of PLGA-PEG conjugate
was also added to ensure PEG modification and prevent clearance
by the reticuloendothelial system. Combination NPs were
synthesized with a 10:1 molar ratio of LON to PTX. A Hitachi
S-4800 microscope was used to obtain SEM images of the NPs.
CremophorH EL (polyoxyethylated castor oil) was used to
prepare drug SOL stocks. Each mL contained 527 mg of
CremophorH EL (BASF, Mount Olive, NJ, USA), 49.7% (v/v)
dehydrated alcohol, USP (Thermo Fisher Scientific, Waltham,
MA), 3 mg PTX, and 12 mg LON.
Cell Culture and Hypoxia
The MDA-MB-231 cells were obtained from ATCC (Manassas,
VA), they were incubated at 37uC and maintained in RPMI-1640
media (Mediatech, Inc; Manassas, VA) supplemented with 1%
penicillin/streptomycin/amphotericin B mixture (Lonza; Walk-
Figure 7. Immunohistochemistry of EGFR and CD-31. Tissue sections were probed with primary antibodies against the protein of interest, then
labeled with Alexa FluorH 488 conjugated secondary antibodies (green). F-actin was stained with Alexa FluorH 568 phalloidin (red) and nuclei were
stained with Hoechst 33342 (blue).
doi:10.1371/journal.pone.0024075.g007
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West Sacramento, CA). A low-oxygen gas (0.5% O2,5 %C O 2,
nitrogen balanced) was used to create hypoxic conditions; cell
culture flasks were placed in a modular incubation chamber
(Billups-Rothenberg, Inc.; Del Mar, CA), flushed with the gas for
five minutes, and incubated at 37uC for five days.
Animals and Orthotopic Model Development
The protocol for animal experiments described in this article
was approved by Northeastern University’s Institutional Animal
Care and Use Committee (protocol#: 09-0724R). Female nu/nu
mice purchased from Charles River Laboratories (Wilmington,
MA) were housed in sterile cages on a 12:12 light/dark cycle with
ad libitum acess to food and water. Hypoxic pre-conditioned
MDA-MB-231 cells were used to establish MDR tumor xeno-
grafts; mice were anesthetized with isoflurane and 2 million
hypoxic MDA-MB-231 cells suspended in a 100 ml of a 50:50 mix
of matrigel and serum free medium was injected into the
mammary fat pad of the mice using pre-chilled, sterile syringes
with 27 gauge, K’’ needles. Vernier calipers were used to measure
tumor size every other day post-inoculation. Tumor volume (V)
was calculated using the formula V = [length6(width)
2]/2 where
length is the longest diameter and width is the shortest diameter
perpendicular to length.
Animals, Treatment, and Tissue Preparation
When tumors reached a volume of 100 mm
3, the mice were
randomly selected for experimental treatment. Treatment was
administered as a single tail vein injection; a 125 mL dose of
80 mg/kg LON and 20 mg/kg PTX. In addition to the eight
treatment groups, a control group of mice without tumors were
also included for the blood analysis. Four mice were included in
each group.
At day zero (day of treatment initiation), day 14, and day 28
(day of animal sacrifice), 200 mL of blood was collected via retro-
orbital bleeding. Mice were anesthetized by isoflurane inhalation
and StatSpinH Microtubes (StatSpin, Inc., Norwood, MA) and
capillaries were used for blood collection. Commercially available
kits and their corresponding methods were used to measure
plasma LDH and ALT; QuantiChromTM Lactate Dehydroge-
nase Kit (BioAssay Systems, Hayward, CA) and Liquid ALT
(SGPT) Reagent Set (Pointe Scientific, Canton, MI).
After 4 weeks of treatment (day 28) animals were euthanized via
isoflurane anesthesia overdose followed by carbon dioxide
inhalation. After euthanasia, the tumor mass was collected and
weighed, then prepared for IHC analysis.
Immunohistochemistry of Tumors
Tumors were excised, embedded in tissue section medium
(Richard-Allan Neg 50*, Thermo Scientific, Waltham, MA), flash
frozen in liquid nitrogen, and stored at 280uC until use. Prior to
cryo-sectioning, tumors were thawed to 220uC, then cut into
7 mm thick sections, mounted onto glass slides (SuperFrost PlusH,
Thermo Scientific, Waltham, MA), outlined with an Aqua Hold
Pap Pen (Scientific Device Laboratory, Des Plaines, IL), and air
dried at room temperature. Sections were then fixed in ice-cold
Figure 8. Immunohistochemistry of HXK2 and SCF. Tissue sections were probed with primary antibodies against the protein of interest, then
labeled with Alexa FluorH 488 conjugated secondary antibodies (green). F-actin was stained with Alexa FluorH 568 phalloidin (red) and nuclei were
stained with Hoechst 33342 (blue).
doi:10.1371/journal.pone.0024075.g008
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rinsed in two changes of cold PBS (5 minutes each), and incubated
with 100 ml of IHC SelectH Blocking Reagent (Chemicon,
Billerica, MA) in a humidified chamber at 37uC for 30 minutes.
The slides were rinsed in PBS and each section was incubated
overnight at 4uC with 100 ml of primary antibody diluted in IHC
SelectH Antibody Diluent Solution (Chemicon, Billerica, MA).
Slides were rinsed in two changes of PBST, each section was
incubated with 100 ml of secondary antibody diluted in IHC
SelectH Antibody Diluent Solution at room temperature for 30
minutes, slides were washed in two changes of PBS then incubated
with a SOL of Alexa FluorH 568 phalloidin (to stain F-actin) and
Hoechst 33342 (to stain nuclei) (Invitrogen; Carlsbad, CA) for 20
minutes, and then slides were rinsed with PBST and dehydrated in
95% ethanol for 2 minutes and 100% ethanol for two exchanges (3
minutes each). Tissue sections were mounted with Prolong GoldH
Antifade reagent (Invitrogen; Carlsbad, CA). All primary antibod-
ies were from Cell Signaling Technology (Danvers, MA) while the
secondary antibodies were Alexa FluorH 488 goat anti-mouse IgG
(H+L) and Alexa FluorH 488 goat anti-rabbit IgG (H+L)
(Invitrogen; Carlsbad, CA). An Olympus IX51 Microscope was
used to image the tissue sections.
Hematoxylin and Eosin Staining of Tumor Sections
Tissue slices were prepared and fixed according to the methods
described above. After fixing in acetone the slides were immersed
in 100% ethanol for 5 minutes, rinsed with water for 5 minutes,
and then incubated with hematoxylin for 10 minutes in a light
protected container. Slides were then rinsed with water for 10
minutes, dipped into a jar of 0.1% HCl 3 times, and dipped into
water 3-4 times. This was followed by dipping the slides in; 0.1%
ammonium hydroxide 3 times, into water 4 times, and in eosin for
3 minutes. Slides were then dipped into ethanol with 0.1% acetic
acid five times, two exchanges of 100% ethanol five times each,
two changes of acetone five times each, and then two exchanges of
xylene-substitute five times each. Two drops of mounting agent
was applied to each tissue section and they were covered with glass
coverslips.
Statistical Analysis and Graphing
GraphPad PrismH Software was used for all graphs and
statistical analysis. A two-way ANOVA was used to analyze the
efficacy data.
Supporting Information
Figure S1 Toxicity analysis at day 0, day 14, and day 28.
Liver enzymes (LDH and ALT) and blood counts were used to
assess toxicity. For all graphs, *p,0.05, **p,0.01, ***p,0.0001.
(A) LDH. The asterisks above the bars indicate significance
between Saline and the indicated group. Not shown: significance
between the No Tumor group and all treatment groups at 14 days
(p,0.01) and 28 days (p,0.05). (B) ALT. The asterisks directly
above the error bars (with no brackets) indicate significance
between Saline and the indicated group. Not shown: significance
between the No Tumor group (as well as the Vehicle group) and
all solution groups at 14 days (p,0.01 for No Tumor comparison,
p,0.05 for Vehicle comparison). (C) White Blood Cell (WBC)
Counts. The asterisks directly above the error bars (with no
brackets) indicate significance between Saline (as well as Vehicle)
and the indicated group. The asterisks directly below the No
Tumor bars indicate significance between the No Tumor group
and all treatment groups for each time point. (D) Platelet Counts.
The asterisks directly above the error bars (with no brackets)
indicate significance between the No Tumor group and the
indicated group. The significance indicated by the brackets (for
Saline v. each solution group) is the same for Vehicle v. solution
groups.
(TIF)
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